Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177 Lu-J591) for Metastatic Castration-Resistant Prostate Cancer.
CONCLUSION: Hyperfractionation of 177 Lu-J591 is feasible but does not seem to have significant advantages over the two-dose fractionation regimen. PMID: 31999003 [PubMed - as supplied by publisher]
CONCLUSIONS: HDT led to a decrease in AR copy number and mutations which was independent from responses to therapy. Further understanding of the genomic alterations as potential predictor of response to HDT is needed. PMID: 32002120 [PubMed]
AbstractPurposeThe aim of this study was to evaluate safety and therapeutic efficacy of lutetium 177 prostate-specific membrane antigen (Lu-177-PSMA) in metastatic castration-resistant prostate cancer (mCRPC) patients with low performance status.MethodsTwenty-two patients already treated with anti-androgens and docetaxel were enrolled for one cycle of Lu-177-PSMA therapy. Haemoglobin, total leukocyte counts, platelets and serum creatinine for toxicity profile while prostate specific antigen (PSA), Eastern Cooperative Oncology Group (ECOG) performance status, visual analogue scale (VAS) and analgesic quantification scale (A...
CONCLUSIONS: Everolimus demonstrated predictable toxicity in advanced and heavily pretreated patients with mCRPC. No clinical or clear pathologic effects despite downstream TORC1 target inhibition, suggesting that single agent everolimus has no clinical utility in men with mCRPC. PMID: 31522863 [PubMed - as supplied by publisher]
Abstract Apoptosis is one of the major mechanisms exhibited in response to cell death and induction of apoptosis in tumour cells signifies a potential target for cancer therapy. Bcl-2 family proteins play a key role in regulation of the apoptotic pathway. Bcl-2 overexpression is commonly associated with various cancers including breast cancer, prostate cancer, B-cell lymphomas and colorectal adenocarcinomas etc. Thus, Bcl-2 is a novel anti-cancer target attracting medicinal chemists across the globe. Research investigations underlying Bcl-2 target have resulted in the generation of small molecule inhibitors, named...
CONCLUSIONS: Based on safety and tolerability, mivebresib RP2D is 1.5mg for the daily schedule, 2.5mg for 4/7 and 3mg for M-W-F. Mivebresib has a tolerable safety profile and stable disease was observed in some patients with malignant solid tumors. PMID: 31420359 [PubMed - as supplied by publisher]
ConclusionsRadium-223 was generally well tolerated and there were no safety concerns. The adverseevents were mild and manageable. A decline in serum alkaline phosphatase was more frequent than a decline in the prostate-specific antigen. Monitoring changes in serum alkaline phosphatase dynamics may be useful.ResumenEl dicloruro de Ra223 es un radiofármaco emisor alfa que prolonga la supervivencia global en pacientes con cáncer de próstata resistente a la castración y metástasis óseas sintomáticas. Presentamos un análisis retrospectivo de 68 pacientes tratados.Mé...
Conclusion: A factor 3–4 lower treatment activity for 90Y-PSMA-617 translates into a comparable dosimetry estimate and clinical findings similar to those of 177Lu-PSMA-617. However, safety was demonstrated only for patients with oligometastatic disease. Further studies are needed to evaluate its potential in patients with more disseminated bone involvement or visceral metastasis.
Conclusions: TANDEM-PLRT, concomitantly administering Ac-225 and Lu-177 PSMA-617, seems to be feasible, safe and effective in end-stage metastatic prostate cancer, refractory to Lu-177 PSMA. The administered radioactivity of Ac-225 PSMA can be lowered and the risk of dose-limiting toxicity (xerostomia, xerophthalmia etc.) be minimized. There might be a potential synergistic effect using two radionuclides with different emission characteristics.
Conclusions: We concluded that Lu177 PSMA therapy has adequate pain palliation in all end-stage mCRPC patients and it has the potential to become an effective therapeutic option in properly selected patients. Keywords: Lu177 PSMA, Safety, efficacy, mCRPC, Low-performance status
Conclusions: Our findings show that 177Lu-PSMA-I&T therapy has early promising response rates and low toxicity in men with mCRPC who have progressed after conventional treatments in our local setting.